|
1
|
Copeland LJ: Epithelial ovarian cancer.
Clin Gynecol Oncol. 7:313–367. 2007. View Article : Google Scholar
|
|
2
|
Holschneider CH and Berek JS: Ovarian
cancer: Epidemiology, biology, and prognostic factors. Semin Surg
Oncol. 19:3–10. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang B, Liu SZ, Zheng RS, Zhang F, Chen WQ
and Sun XB: Time trends of ovarian cancer incidence in China. Asian
Pac J Cancer Prev. 15:191–193. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shushan A, Paltiel O, Iscovich J, Elchalal
U, Peretz T and Schenker JG: Human menopausal gonadotropin and the
risk of epithelial ovarian cancer. Fertil Steril. 65:13–18. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Daniilidis A and Karagiannis V: Epithelial
ovarian cancer. Risk factors, screening and the role of
prophylactic oophorectomy. Hippokratia. 11:63–66. 2007.PubMed/NCBI
|
|
6
|
Survival of Cancer Patients in Europe: The
EUROCARE-2 study. IARC Sci Publ 1–572. 1999.
|
|
7
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in Cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong
Q, Qin L, Wu X, Zheng Y, Yang Y, et al: Identification of miRNomes
in human liver and hepatocellular carcinoma reveals miR-199a/b-3p
as therapeutic target for hepatocellular carcinoma. Cancer Cell.
19:232–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li D, Liu X, Lin L, Hou J, Li N, Wang C,
Wang P, Zhang Q, Zhang P, Zhou W, et al: MicroRNA-99a inhibits
hepatocellular carcinoma growth and correlates with prognosis of
patients with hepatocellular carcinoma. J Biol Chem.
286:36677–36685. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mendell JT and Olson EN: MicroRNAs in
stress signaling and human disease. Cell. 148:1172–1187. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Resnick KE, Alder H, Hagan JP, Richardson
DL, Croce CM and Cohn DE: The detection of differentially expressed
microRNAs from the serum of ovarian cancer patients using a novel
real-time PCR platform. Gynecol Oncol. 112:55–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chung YW, Bae HS, Song JY, Lee JK, Lee NW,
Kim T and Lee KW: Detection of microRNA as novel biomarkers of
epithelial ovarian cancer from the serum of ovarian cancer
patients. Int J Gynecol Cancer. 23:673–679. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shapira I, Oswald M, Lovecchio J, Khalili
H, Menzin A, Whyte J, Dos Santos L, Liang S, Bhuiya T, Keogh M, et
al: Circulating biomarkers for detection of ovarian cancer and
predicting cancer outcomes. Br J Cancer. 110:976–983. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suryawanshi S, Vlad AM, Lin HM,
Mantia-Smaldone G, Laskey R, Lee M, Lin Y, Donnellan N, Klein-Patel
M, Lee T, et al: Plasma microRNAs as novel biomarkers for
endometriosis and endometriosis-associated ovarian cancer. Clin
Cancer Res. 19:1213–1224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng H, Zhang L, Zhao Y, Yang D, Song F,
Wen Y, Hao Q, Hu Z, Zhang W and Chen K: Plasma miRNAs as diagnostic
and prognostic biomarkers for ovarian cancer. PLoS One.
8:e778532013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kan CW, Hahn MA, Gard GB, Maidens J, Huh
JY, Marsh DJ and Howell VM: Elevated levels of circulating
microRNA-200 family members correlate with serous epithelial
ovarian cancer. BMC Cancer. 12:6272012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Giordano S and Columbano A: MicroRNAs: New
tools for diagnosis, prognosis, and therapy in hepatocellular
carcinoma? Hepatology. 57:840–847. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song B, Ji W, Guo S, Liu A, Jing W, Shao
C, Li G and Jin G: miR-545 inhibited pancreatic ductal
adenocarcinoma growth by targeting RIG-I. FEBS Lett. 588:4375–4381.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Du B, Wang Z, Zhang X, Feng S, Wang G, He
J and Zhang B: MicroRNA-545 suppresses cell proliferation by
targeting cyclin D1 and CDK4 in lung cancer cells. PLoS One.
9:e880222014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yiwei T, Hua H, Hui G, Mao M and Xiang L:
HOTAIR interacting with MAPK1 regulates ovarian cancer skov3 cell
proliferation, migration, and invasion. Med Sci Monit.
21:1856–1863. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Song B, Zhang C, Li G, Jin G and Liu C:
MiR-940 inhibited pancreatic ductal adenocarcinoma growth by
targeting MyD88. Cell Physiol Biochem. 35:1167–1177. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou Q and Yu Y: Upregulated CDK16
expression in serous epithelial ovarian cancer cells. Med Sci
Monit. 21:3409–3414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li H, Xu Y, Qiu W, Zhao D and Zhang Y:
Tissue miR-193b as a novel biomarker for patients with ovarian
cancer. Med Sci Monit. 21:3929–3934. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife: Aug. 12:42015.
|
|
29
|
Cristiano BE, Chan JC, Hannan KM, Lundie
NA, Marmy-Conus NJ, Campbell IG, Phillips WA, Robbie M, Hannan RD
and Pearson RB: A specific role for AKT3 in the genesis of ovarian
cancer through modulation of G2-M phase transition. Cancer
Research. 66:11718–11725. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang L, Volinia S, Bonome T, Calin GA,
Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K,
et al: Genomic and epigenetic alterations deregulate microRNA
expression in human epithelial ovarian cancer. Proc Natl Acad Sci
USA. 105:pp. 7004–7009. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang H, Kong W, He L, Zhao JJ, O'Donnell
JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV and Cheng JQ:
MicroRNA expression profiling in human ovarian cancer: miR-214
induces cell survival and cisplatin resistance by targeting PTEN.
Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li N, Zhao X, Wang L, Zhang S, Cui M and
He J: miR-494 suppresses tumor growth of epithelial ovarian
carcinoma by targeting IGF1R. Tumor Biol. 37:7767–7776. 2016.
View Article : Google Scholar
|
|
34
|
Yuan J, Wang K and Xi M: MiR-494 inhibits
epithelial ovarian cancer growth by targeting c-Myc. Med Sci Monit.
22:617–624. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Song B, Ji W, Guo S, Liu A, Jing W, Shao
C, Li G and Jin G: miR-545 inhibited pancreatic ductal
adenocarcinoma growth by targeting RIG-I. FEBS Lett. 588:4375–4381.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liao C, Xiao W, Zhu N, Liu Z, Yang J, Wang
Y and Hong M: MicroR-545 enhanced radiosensitivity via suppressing
Ku70 expression in Lewis lung carcinoma xenograft model. Cancer
Cell Int. 15:562015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chin YR, Yoshida T, Marusyk A, Beck AH,
Polyak K and Toker A: Targeting Akt3 signaling in triple-negative
breast cancer. Cancer Res. 74:964–973. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lin HP, Lin CY, Huo C, Jan YJ, Tseng JC,
Jiang SS, Kuo YY, Chen SC, Wang CT, Chan TM, et al: AKT3 promotes
prostate cancer proliferation cells through regulation of Akt,
B-Raf, and TSC1/TSC2. Oncotarget. 6:27097–27112. 2015. View Article : Google Scholar : PubMed/NCBI
|
